丝裂霉素C作为局部眼表鳞状上皮肿瘤治疗的辅助药物。
Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.
作者信息
Chen C, Louis D, Dodd T, Muecke J
机构信息
Ophthalmic Oncology Unit, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia.
出版信息
Br J Ophthalmol. 2004 Jan;88(1):17-8. doi: 10.1136/bjo.88.1.17.
AIM
To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).
METHOD
Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period.
RESULT
27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12-50, median 25 months) revealed zero recurrences.
CONCLUSION
MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.
目的
报告丝裂霉素C（MMC）局部应用作为眼表鳞状上皮肿瘤（OSSN）初次切除术后辅助治疗的效果。
方法
对一个眼科肿瘤中心4年内收治的26例患者的27个原发性OSSN病变进行前瞻性、非对比性干预病例系列研究。
结果
27例OSSN患者接受了手术切除联合MMC局部应用的治疗方案。平均随访27（标准差12）个月（范围12 - 50个月，中位数25个月），未见复发。
结论
手术切除后应用MMC治疗可降低原发性眼表肿瘤的复发率，应作为原发性治疗的辅助疗法。
Zotero 插件